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Abstract
Zinc-a2-glycoprotein (ZAG, also listed as AZGP1 in the MGI
Database),alipid-mobilisingfactor,hasrecentlybeensuggested
as a potential candidate in the modulation of body weight. We
investigatedtheeffectofincreasedadiposityonZAGexpression
in adipose tissue and the liver and on plasma levels in obese
(ob/ob) mice compared with lean siblings. The study also
examined the effect of the pro-inﬂammatory cytokine tumour
necrosis factor-a (TNFa) on ZAG expression in adipocytes.
Zag mRNA levels were signiﬁcantly reduced in subcutaneous
(fourfold) and epididymal (eightfold) fat of ob/ob mice.
Consistently, ZAG protein content was decreased in both fat
depots of ob/ob mice. In the liverof obese animals, steatosis was
accompaniedbythefallofbothZagmRNA(twofold)andZAG
protein content (2.5-fold). Plasma ZAG levels were also
decreased in obese mice. In addition, Zag mRNAwas reduced
in epididymal (ﬁvefold) and retroperitoneal (ﬁvefold) adipose
tissueofobese(fa/fa)Zucker rats.IncontrasttoZagexpression,
Tnfa mRNA levels were elevated in adipose tissue (twofold)
and the liver (2.5-fold) of ob/ob mice. Treatment with TNFa
reduced Zag gene expression in differentiated adipocytes, and
this inhibition was chronic, occurring at 24 and 48 h following
TNFatreatment. Itisconcluded thatZAGsynthesisinadipose
tissueand theliver isdownregulated,as areitscirculatinglevels,
in ob/ob mice. The reduced ZAG production may advance the
susceptibility to lipid accumulation in these tissues in obesity,
and this could be at least in part attributable to the inhibitory
effect of TNFa.
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Introduction
Obesity is now a major health problem as it predisposes to
insulin resistance, type 2 diabetes and cardiovascular
malfunction. Although the pathogenesis of obesity and
its associated co-morbidities are multifactorial, growing
evidence suggests that altered production of adipose-derived
protein factors (adipokines), such as leptin, tumour necrosis
factor-a (TNFa), adiponectin and chemerin, plays an
important role. Zinc-a2-glycoprotein (ZAG, also called
AZGP1) is a secreted, soluble protein that has been found
in plasma and other body ﬂuids in humans (Burgi & Schmid
1961, Tada et al. 1991). Crystal structure analysis has
demonstrated that ZAG belongs to the major histocompat-
ibility complex (MHC) class I family (Sanchez et al. 1999).
Unlike other MHC molecules, ZAG is not membrane
bound, and its functions seem to differ from that of MHC
class I molecules (Sanchez et al. 1999, McDermott et al.
2006). Although the biological roles of ZAG have not been
fully characterised, the protein has been shown to be identical
to a lipid-mobilising factor (LMF), puriﬁed from the urine of
patients with cancer cachexia (Todorov et al.1 9 9 8 ).
Treatment with puriﬁed ZAG causes a selective reduction
in body fat in both obese (ob/ob) and normal mice (Hirai et al.
1998, Bing et al. 2002). In vitro, ZAG stimulates lipolysis in
isolated murine and human adipocytes, and this appears to be
attributable to its signalling through b3-adrenoceptors in
rodents(Hiraietal.1998).Further,thereisevidencethatZAG
directly promotes lipid utilisation, possibly by the upregula-
tion of mitochondrial uncoupling proteins (Bing et al. 2002).
ZAG has been identiﬁed in various organs, including the
liver, breast, lung and prostate (Tada et al. 1991). Recent work
from our group has shown that ZAG is also expressed in
mouse, rat and human adipose tissue (Bing et al. 2004,
Tzanavari et al. 2007). Importantly, ZAG is secreted
abundantly from mature adipocytes as a major adipokine
which may have an autocrine/paracrine role in adipose tissue
function (Bao et al. 2005, Mracek et al. 2009). ZAG
expression in adipose tissue appears to be inversely linked to
body fat mass. ZAG mRNA and protein content in adipose
tissue are markedly increased in mice with cancer cachexia
(Bing et al. 2004, 2006). In contrast, ZAG protein expression
is reduced in white fat of neonatal rats at weaning when there
is a rise in fat mass (Tzanavari et al. 2007). Furthermore, ZAG
mRNA levels have been reported to be decreased in
subcutaneous fat of obese women (Dahlman et al. 2005) and
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group and by others has shown that ZAG mRNA is
negatively correlated with body mass index and body fat
mass in human subjects (Gong et al. 2009, Mracek et al. 2009,
Selva et al. 2009). In addition to adipose tissue, the liver is also
a major site of ZAG synthesis in rodents (Ueyama et al. 1994,
Bing et al. 2004). However, the regulation of ZAG expression
in adipose tissue and the liver and of the circulating levels in
obesity remains to be established.
The aim of this study was to examine the effect of increased
adiposity on ZAG gene and protein expression in adipose
tissue and liver of obese (ob/ob) mice in comparison with their
lean siblings (ob/C). Plasma ZAG protein levels were also
determined in these mice. Finally, the study explored the
effect of the pro-inﬂammatory cytokine TNFa on ZAG
expression in adipocytes.
Materials and Methods
Animals
Nine-week-old male C57BL/6 obese (ob/ob; B6.V-Lep
ob/
OlaHsd) and appropriate lean control (B6.V-Lep
ob/
CLep
COlaHsd) mice from Harlan (Bicester, UK) were
housed at an ambient temperature of 22G1 8C under a 12 h
light:12 h darkness cycle (lights on at 0700 h) and were fed ad
libitum (CRM Diet, Labsure, Poole, UK). The ﬁnal body
weightofobeseandleanmice(nZ8pergroup)wasrecordedas
39.2G0.7vs24.6G0.4(g)(meanGS.E.M).Micewerekilledby
cervical dislocation. Adipose tissue (epididymal and subcu-
taneous) and liver were rapidly dissected and frozen in liquid
nitrogen. Blood samples were collected and centrifuged to
obtain plasma. The tissues and plasma were stored at K80 8C
until analysis. Adipose tissue (epididymal and retroperitoneal)
from 3-month-old male Zucker rats (lean: C/C or fa/C and
obese: fa/fa) bred at the Rowett Research Institute (Aberdeen,
Scotland) were kindly provided by Dr Varner Rayner. All the
animal studies were carried out according to the UK Home
OfﬁceGuidelinesforthecareanduseoflaboratoryanimalsand
in accordance with the provisions of the United Kingdom
Animals (Scientiﬁc Procedures) Act 1986.
Cell culture
Simpson–Golabi–Behmel syndrome (SGBs) cells (kindly
provided by Prof. M Wabitsch, University of Ulm, Germany)
weremaintainedandculturedasdescribedpreviously(Wabitsch
etal.2001).Inbrief,cellswereculturedat37 8Cinahumidiﬁed
atmosphere of 5% CO2/95% air. SGBS preadipocytes were
maintained in DMEM/Ham’s F12 (1:1) medium (Invitrogen)
containing 10% (v/v) FCS (Sigma) and antibiotics (penicillin/
streptomycin, Lonza, Tewkesbury, UK). Preadipocytes were
seeded onto 12-well plates and grown until conﬂuence. At
conﬂuence, cells were induced to differentiate (day 0) by
incubationfor5daysinFCS-freemediumcontaining0.25 mM
dexamethasone, 500 mM 3-isobutyl-1-methyl-xanthine,
10 nM insulin, 200 pM triiodothyronine (T3), 1 mM cortisol
(all from Sigma) and 2 mM rosiglitazone (GlaxoSmithKline).
After induction, cells were further maintained in feeding
medium(containing10 nMinsulin,1 mMcortisoland200 pM
T3,allfromSigma)untilfulldifferentiation.Differentiationinto
adipocytes was visualised under the microscope by observing
theaccumulationoflipiddroplets.Thedifferentiatedcellsatday
14 after the induction of differentiation were treated with
30 ng/ml recombinant human TNFa (Sigma) for 24 h. The
controlcells receivednoaddition. For the time-course studyof
the effect of TNFa on ZAG expression in adipocytes, cells at
day14post-differentiationwereincubatedinmediacontaining
TNFa (25 ng/ml) up to 48 h. No reagent was added to the
mediaofcontrolcells.Cellswerecollectedatthetimepointsof
0, 2, 4, 6, 8, 12, 24 and 48 h.
Histology
Liver samples from ob/ob and lean mice were ﬁxed in 10%
neutral formalin for 24 h, dehydrated in absolute ethanol,
cleared in xylene and then embedded in parafﬁn. The parafﬁn
was cut into 5-mm sections that were stained with Harris
haematoxylin, counterstained with eosin, and then evaluated
and photographed under light microscopy.
Real-time PCR for mRNA quantiﬁcation
Total RNA was extracted from tissues and cells using TRI
reagent (Sigma), and the RNA concentration was determined
from the absorbance at 260 nm. First strand cDNA was
reverse transcribed from 0.5 mg of total RNA using an iScript
ﬁrst strand synthesis kit (Bio-Rad) in a ﬁnal volume of 10 ml.
Real-time PCR ampliﬁcation was performed in a ﬁnal
volume of 12.5 ml, containing cDNA (equivalent to 10 ng of
RNA), optimised concentrations of primers, TaqMan probe
FAM-TAMRA and a master mix made from qPCR core kit
(Eurogentec, Seraing, Belgium) using a Stratagene Mx3005P
instrument. The sequences of primers and probes for mouse
ZAG, leptin, TNFa and b-actin, and rat ZAG, leptin and
b-actin, and human ZAG, adiponectin and b-actin were as
described previously (Bing et al. 2004, 2006, Bao et al. 2005,
Tzanavari et al. 2007). PCR ampliﬁcation was performed in
duplicateusing96-wellplates,andthePCRcyclingconditions
wereasfollows:95 8Cfor10 minfollowedby40cycles(95 8C
for 15 s and 60 8C for 1 min). Blank controls without cDNA
were run in parallel. b-Actin was used as a reference gene. All
samples were normalised to the b-actin values, and the results
are expressed as fold changes of Ct value relative to controls
using the 2KDDCt formula (Schmittgen & Livak 2008).
Recombinant mouse ZAG protein
Recombinant mouse ZAG protein was used as a positive
control for the detection of ZAG protein by western blotting.
Full-length mouse Zag cDNA in the pCMV-SPORT6 vector
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plasmid (Invitrogen) and was subsequently transfected into
HEK-293 cells using Metafectene Pro reagent (Biontex,
Planegg, Germany). Twenty-four hours after transfection, the
cells were transferred into serum-free DMEM. Medium
containing secreted ZAG protein was collected every day for
four consecutive days. ZAG-conditioned medium was
concentrated on Amicon Ultra 15 columns with a 30 k cut-
off (Millipore, Watford, UK). Successful ZAG overexpression
was conﬁrmed by western blot analysis.
Western blotting
Protein samples were prepared from mouse white adipose
tissue (WAT) and liver. Homogenates of these samples were
prepared in isoosmotic buffer (250 mM sucrose, 10 mM Tris–
HCl and 1 mM EDTA, pH 7.4), and the protein
concentration was determined by the BCA method. For
plasma ZAG detection, 0.5 ml of plasma was used for each
sample. Tricine–SDS electrophoresis of the samples was
performed on 10% polyacrylamide slab gels (Mini Protean
Tetra, Bio-Rad) using the same aliquots of SDS-solubilised
proteins (20–30 mg/slot). Proteins from the gel were blotted
onto a nitrocellulose membrane (Hybond C Extra, GE
Healthcare, Little Chalfont, UK) by wet transfer (Trans Blot,
Bio-Rad) at 100 V for 1 h. The transfer of proteins onto the
membrane was assessed by Ponceau S staining.
For immunodetection of ZAG, the membranes were
blocked overnight at 4 8C with TBS (0.15 M NaCl and
20 mM Tris, pHZ7.6) containing 0.1% Tween 20 and 5%
non-fat milk (TBSTM) and were then incubated overnight at
4 8C with polyclonal goat anti-mouse ZAG antibody (1:500;
Santa Cruz Biotechnology, Santa Cruz, CA, USA; sc-11243)
in TBSTM. The membranes were then incubated for 1 h
using donkey anti-goat IgG (1:1000; R&D Systems,
Abingdon, UK; HAF109) secondary antibody conjugated
with HRP in TBSTM. For the detection of cytochrome
oxidase subunit IV (COX IV), succinate dehydrogenase
70 kDa subunit (SDH 70), glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), and a-tubulin or b-actin (used as
a loading control), the conditions were as follows: membranes
were blocked with TBS containing 0.1% Tween 20 and 2%
BSA (TBSTA) for 1 h and were incubated for 2 h with the
primary monoclonal antibody diluted in TBSTA: anti-COX
IV subunit of Complex IV (1:1000; Mito Sciences, Eugene,
OR, USA; MS 407), anti-SDH 70 (1:1000; Mito Sciences,
MS 204), anti-GAPDH (1:5000; Sigma), anti-a-tubulin
(1:2000; Sigma) and anti-b-actin (1:2000; Sigma). Sub-
sequently, membranes were incubated with secondary
HRP-conjugated rabbit anti-mouse IgG (1:2000; Bio-Rad)
diluted in TBSTA for 1 h. Signals were detected on ﬁlm
by chemiluminescence (West Pico kit, Perbio Science,
Cramlington, UK). The size of the protein bands detected
was estimated with PageRuler protein markers (Fermentas,
York, UK). Plasma ZAG levels were normalised to total
protein concentration.
Liver triglyceride measurement
The triglyceride levels in mouse liver were determined by a
colorimetric method using a triglycerides assay kit from
Randox (Antrim, UK) according to the manufacturer’s instruc-
tions. Liver triglyceride levels are normalised to protein content.
Statistical analysis
Data are expressed as meansGS.E.M. Differences between two
groups were analysed by Student’s unpaired t-test; differences
were considered as statistically signiﬁcant when P!0.05.
Results
ZAG gene and protein expression in adipose tissue of ob/ob mice
To examine whether ZAG expression in adipose tissue is
altered in obesity, we ﬁrst determined the relative Zag
mRNA levels by real-time PCR in two major WAT depots
(subcutaneous and epididymal) of ob/ob mice and their lean
siblings. Zag mRNA levels were signiﬁcantly reduced in
both subcutaneous (fourfold, P!0.05) and epididymal
(eightfold, P!0.05) fat depots of ob/ob mice compared
with lean controls (Fig. 1A). In contrast, leptin mRNA levels,
Figure 1 Zag gene expression in adipose tissue of ob/ob and lean
mice. Total RNA was extracted from subcutaneous and epididymal
fat pads of lean (ob/C) and ob/ob mice, and mRNA levels of
(A) Zag and (B) leptin were measured by real-time PCR and
normalised to b-actin. Results are expressed as meansGS.E.M. for
groups of 6. *P!0.05, ***P!0.001 compared with lean controls.
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depots of ob/ob mice (subcutaneous: ninefold, P!0.001;
epididymal: fourfold, P!0.05; Fig. 1B).
ZAG protein expression in adipose tissue of mice was
assessed next by western blotting. Consistent with the data on
Zag gene expression, there were decreases in ZAG protein
levels in subcutaneous (K29%, P!0.05) and epididymal
(K34%, P!0.001) fat of ob/ob mice relative to their lean
controls (Fig. 2A and B). We also determined the levels of
COX IVand SDH 70 protein as a measure of mitochondrial
oxidative phosphorylation capacity in adipocytes (Choo et al.
2006). Protein expression of COX IV and SDH 70 in ob/ob
mice was unchanged (both PO0.05; Fig. 2A and B) in the
fat depots.
ZAG gene and protein expression in liver of ob/ob mice
Liver histology revealed the typical features of steatosis (fatty
liver) in ob/ob mice, which is characterised by the intracellular
accumulation of multiple lipid droplets in hepatocytes
(Fig. 3A). Concurrently, liver triglyceride content was
signiﬁcantly higher in obese mice than in lean siblings
(4.2-fold, P!0.001; Fig. 3B). Since the liver is another
major source of ZAG production, we further examined ZAG
synthesis in liver of obese and lean mice. Zag mRNA levels
were twofold lower (P!0.01) in ob/ob mice relative to lean
mice (Fig. 3D). Consistent with the mRNA result, ZAG
protein levelswere2.5-folddecreasedin ob/obmicecompared
with the lean controls (P!0.05; Fig. 3C and E). In contrast,
GAPDH protein in the liver was increased by 4.8-fold
(P!0.05) in obese animals (Fig. 3C and F).
Plasma ZAG levels in ob/ob mice
To examine whether the circulating levels of ZAG are altered
in ob/ob mice, plasma ZAG protein was measured by western
blotting. Plasma ZAG protein levels were lower (by 23%,
P!0.001) in obese mice than in lean mice (Fig. 4A and B).
ZAG expression in adipose tissue of Zucker rats
Consistent with the results in ob/ob mice, Zag mRNA levels
were signiﬁcantly reduced in both epididymal and retro-
peritoneal fat depots (by ﬁvefold, P!0.05) in fa/fa Zucker
rats relative to the lean controls (Fig. 5A and B). In contrast,
leptin mRNA levels were elevated in retroperitoneal fat (by
2.5-fold, P!0.05) in fa/fa rats compared with their lean
counterparts (Fig. 5C).
Tnfa mRNA levels in adipose tissue and liver of ob/ob mice
Since TNFa has a key role in obesity-related inﬂammation,
we examined Tnfa gene expression in epididymal fat and
the liver of ob/ob and lean mice. In contrast to the results for
Figure 3 Zag mRNA and protein expression in the liver of ob/ob
and lean mice. (A) Histology of the liver sections stained with H&E
(bar, 50 mm); (B) liver triglyceride content; and (C) representative
western blot of ZAG and GAPDH protein, recombinant mouse ZAG
(mZAG) used as a positive control. (D) Liver Zag mRNA levels
were measured by real-time PCR and normalised to b-actin;
(E) quantiﬁcation of ZAG protein normalised to b-actin and
(F) quantiﬁcation of GAPDHproteinnormalised tob-actin.Dataare
meansGS.E.M. for groups of 7. *P!0.05, **P!0.01 compared with
lean controls.
Figure 2 ZAG protein expression in adipose tissue of ob/ob and
lean mice. Protein was extracted from subcutaneous and epididy-
mal fat of lean (ob/C) and ob/ob mice, and western blotting was
used for protein expression of ZAG, COX IV, SDH 70 and a-tubulin.
Representative western blot and quantiﬁcation of protein
expression normalised to a-tubulin in subcutaneous (A and B) and
epididymal (C and D) fat. Data are meansGS.E.M. for groups of 6.
*P!0.05, ***P!0.001 compared with lean controls.
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(twofold, P!0.001) and liver (twofold, P!0.05) in obese
animals (Fig. 6A and B).
Time-dependent effects of TNFa on Zag gene expression in
differentiated adipocytes
The effect of TNFa on Zag expression was further studied
in differentiated SGBS adipocytes. Consistent with our
previous observation with a higher dose of TNFa
(50 ng/ml; Bao et al. 2005), addition of TNFa (30 ng/ml)
for 24 h led to a reduction in mRNA levels of Zag
(threefold, P!0.001; Fig. 7A) and adiponectin (fourfold,
P!0.001; Fig. 7B), with the latter being used as a reference
gene. We then examined whether the inhibitory effect of
TNFa on Zag expression is time-dependent. As shown in
Fig. 7C, the effect of TNFa on Zag mRNA appeared to be
chronic rather than acute; the reduction in Zag mRNA was
progressive, but it was only signiﬁcant after incubation with
TNFa for 24 (P!0.01) and 48 h (P!0.01).
Discussion
In the present study, a signiﬁcant difference in Zag gene and
its protein expression in white fat between lean and
genetically obese mice has been demonstrated. We found
that Zag mRNA levels are markedly reduced in subcutaneous
and epididymal adipose tissue of ob/ob mice. In contrast,
mRNA levels of the mutated leptin are signiﬁcantly higher in
the two depots of ob/ob mice as reported previously
(Frederich et al. 1995, Trayhurn et al. 1995), reﬂecting the
greater tissue mass and perhaps a compensatory response to
the mutation. Consistent with the gene expression data, we
further demonstrated that ZAG protein expression is
decreased in epididymal and subcutaneous fat of ob/ob mice.
In agreement with our ﬁndings, a recent study has shown
that Zag gene expression was also reduced in epididymal
adipose tissue of obese mice fed with a high-fat diet
Figure 4 Plasma ZAG protein content in ob/ob and lean mice.
Plasma of 0.5 ml was used for western blotting analysis of ZAG
protein. (A) Representative western blot of ZAG protein (upper
panel), and total proteins assessed by Ponceau S staining of the
membrane (lower panel); (B) quantiﬁcation of ZAG protein,
expressed as meansGS.E.M. of signal density normalised by the total
protein concentration relative to lean controls, nZ7 per group.
***P!0.001 compared with lean controls.
Figure 5 Zag gene expression in adipose tissue of obese (fa/fa) and
lean Zucker rats. Zag mRNA levels in epididymal (A) and
retroperitoneal (B) fat, and leptin mRNA levels in retroperitoneal fat
(C) of fa/fa and lean Zucker rats. mRNA levels were measured by
real-timePCR and normalised to b-actin. Data are meansGS.E.M. for
groups of 6–8. *P!0.05 compared with lean controls.
Figure 6 Tnfa gene expression in adipose tissue and liver of ob/ob
and lean mice. Total RNA was extracted from epididymal fat pad
and liver of lean (ob/C) and ob/ob mice, and Tnfa mRNA levels in
(A) epididymal adipose tissue and (B) liver were measured by real-
time PCR and normalised to b-actin. Results are expressed as
meansGS.E.M. for groups of 6. *P!0.05, ***P!0.001 compared
with lean controls.
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we demonstrate that in addition to mouse models of obesity,
Zag mRNA levels in epididymal and retroperitoneal fat are
signiﬁcantly decreased in obese (fa/fa) Zucker rats. Collec-
tively, these observations suggest a possible link between
increased adiposity and the downregulation of Zag expression
in adipose tissue.
Obesity is associated with alterations in basal lipolysis,
impaired antilipolytic action of insulin and reduced lipo-
protein lipase activity (Hauner et al. 2001). Furthermore, the
substantial decrease in the expression and function of b1- and
b3-adrenoreceptors in adipose tissue in ob/ob mice has been
suggested to be a reason for the impaired lipid mobilisation
in response to b-adrenergic agonists (Robidoux et al. 2004).
The repression of ZAG synthesis in obese animals might
be related to its function in modulating lipid metabolism
(Bing & Trayhurn 2008). It has been shown that ZAG
treatment selectively reduces body fat in obese and normal
mice in vivo and stimulates lipolysis in vitro (Hirai et al. 1998,
Bing et al. 2002). It was proposed that ZAG may act as an
alternative b-adrenergic agonist by signalling through
b3-adrenoceptors in rodents (Hirai et al. 1998, Russell et al.
2004). The role of ZAG in lipid mobilisation has been
supported by a recent study of ZAG-knockout mice which
were susceptible to weight gain on a HFD, and this probably
results from a decrease in adipocyte lipolysis (Rolli et al.
2007). In addition, mRNA levels of hormone-sensitive lipase
were elevated in adipose tissue from ZAG-overexpressing
transgenic mice which exhibit decreased body weight
and epididymal fat (Gong et al. 2009). Therefore, reduced
ZAG synthesis in adipose tissue of ob/ob mice observed in
the present study may contribute to an impairment of
lipid mobilisation.
Another interesting ﬁnding of this study is the demon-
stration of a decrease in Zag expression, both mRNA and
protein, in the fatty liver of ob/ob mice. Liver is another major
site for ZAG synthesis in rodents (Ueyama et al. 1994, Bing
et al. 2004). It is of interest that Zag mRNA levels have been
reported to be increased in the liver of mice with cancer
cachexia (Bing et al. 2004), a condition associated with
signiﬁcantly decreased adiposity. Liver steatosis in ob/ob mice,
as shown in the present study and previously (Shimomura
et al. 1999), has been suggested to be the consequence of
impaired lipid mobilisation and enhanced lipogenesis. Given
the role of ZAG as an LMF, the fall of ZAG synthesis in
the liver of obese mice may contribute to the hepatic
accumulation of triglycerides. In addition to alterations in
lipid metabolism, there are signiﬁcant disturbances in liver
glucose metabolism in ob/ob animals. A previous study has
shown that hyperglycaemia in ob/ob mice is characterised by
decreased phosphoenolpyruvate carboxykinase mRNA and
increased Gapdh mRNA levels in the liver (Ferber et al. 1994).
We show here an enhanced expression of GAPDH protein in
the liverof ob/ob mice, which further supports a dysregulation
of hepatic glucose metabolism in obesity.
In the present study, plasma ZAG protein content was
decreased in obese ob/ob mice, and a similar decline was
observed in HFD-fed obese mice (Gong et al. 2009).
Concomitantly, recent studies in humans have reported
reductions in serum ZAG levels in obese patients (Gong
et al. 2009, Selva et al. 2009). However, a study by Stejskal
et al. (2007) has found no differences in serum ZAG
concentrations between obese patients with the metabolic
syndrome and otherwise healthy controls. These results
suggest that adipose tissue- and liver-derived ZAG may be
important locally through its autocrine/paracrine actions.
The production of ZAG in other tissues would inﬂuence its
circulating levels, and also the clearance of ZAG in the
circulation might be altered in obesity.
Although ZAG expression has been shown to be inversely
related to adiposity, its regulation in obesity remains to be
established. Obesity, characterised by a state of chronic
Figure 7 Effects of TNFa on Zag expression in adipocytes. SGBS
cells were harvested at day 14 after the induction of differentiation
and were incubated for 24 h in media containing TNFa (30 ng/ml).
Control cells received no addition. (A) Zag and (B) adiponectin
mRNA levels were measured by real-time PCR, normalised to
b-actin and expressed relative to the controls. Data are means
GS.E.M. forgroupsof 6.**P!0.01comparedwithcontrols.(C) Time
course of the effect of TNFa on Zag mRNA levels in adipocytes.
SGBS cells were differentiated from preadipocytes, and at day 14
post-induction, they were incubated in media containing TNFa
(25 ng/ml) up to 48 h. No reagent was added to the media of control
cells. Zag mRNA levels were measured by real-time PCR. Data are
meansGS.E.M. for groups of 3. **P!0.01, ***P!0.001 compared
with controls.
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of pro-inﬂammatory cytokines (Yudkin et al. 1999). TNFa
has been indicated as a key player in the inﬂammatory
processes (Hotamisligil et al. 1993), and it alters the
production of adipokines, such as inhibiting adiponectin
whilst stimulating the synthesis of pro-inﬂammatory adipo-
kines (Degawa-Yamauchi et al. 2005, Wang & Trayhurn
2006). In the present study, we demonstrate that contrary to
Zag expression, Tnfa mRNA levels are increased in both
adipose tissue and liver in ob/ob mice. The rise in Tnfa with
decreased Zag expression may imply a role for TNFa in the
lowered ZAG production in obesity. This notion is supported
by the in vitro study that shows an inhibitory effect of TNFa
on Zag gene expression in differentiated adipocytes, which
is consistent with our previous observation (Bao et al. 2005).
Therefore, TNFa could be a negative regulator of ZAG
synthesis in adipose tissue. To further characterise the nature
of the inhibitory effect of TNFa on Zag expression, we
assessed the changes over a time course. Our results reveal a
chronic effect of TNFa on ZAG in adipocytes as the apparent
reduction of Zag mRNA occurs at 24 and 48 h following
TNFa treatment. Taken together, these results suggest that
repression of ZAG expression in adipose tissue and possibly in
the liver of obese mice might be the consequence of increased
TNFa in the obese state.
In conclusion, the present study shows that Zag mRNA
and its protein expression in adipose tissue is downregulated
in ob/ob mice. It also demonstrates that in the fatty liver of
obese mice, both Zag mRNA levels and protein content are
reduced. Furthermore, circulating ZAG levels are decreased
in obese mice. In contrast, Tnfa mRNA levels are elevated
in adipose tissue and liver of ob/ob mice. Treatment of
TNFa in vitro represses ZAG expression in differentiated
adipocytes. It is suggested that reduced ZAG production may
advance the susceptibility to lipid accumulation in adipose
tissue and liver in obesity, and this could be at least in part
attributable to the inhibitory effect of TNFa.
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